T1	Condition 32 53	acquired hypogonadism
T2	Condition 18 28;41 53	congenital hypogonadism
T3	Non-representable 54 128	for whom long-term therapy with placebo would not be medically appropriate
*	OR T2 T1
T4	Measurement 148 179	prostate specific antigen (PSA)
T5	Value 180 191	> 3.0 ng/mL
T6	Drug 206 234	5-alpha reductase inhibitors
T7	Value 196 199	1.5
A1	Optional T6
R1	Has_value Arg1:T6 Arg2:T7	
*	OR T5 T6
T8	Scope 180 235	> 3.0 ng/mL (or 1.5 if on 5-alpha reductase inhibitors)
R2	Has_scope Arg1:T4 Arg2:T8	
T9	Drug 277 289	testosterone
T10	Temporal 290 310	in the past 6 months
R3	Has_temporal Arg1:T9 Arg2:T10	
T11	Condition 348 363	contraindicated
T12	Procedure 324 344	testosterone therapy
R4	AND Arg1:T11 Arg2:T12	
T13	Drug 324 336	testosterone
R5	multi Arg1:T12 Arg2:T13	
T14	Measurement 365 387	Confirmed testosterone
T15	Value 388 399	< 100 ng/dL
R6	Has_value Arg1:T14 Arg2:T15	
T16	Measurement 401 422	Body Mass Index (BMI)
T17	Value 423 427	> 50
R7	Has_value Arg1:T16 Arg2:T17	
T18	Measurement 429 451	Hemoglobin A1c (HbA1C)
T19	Value 452 457	> 11%
R8	Has_value Arg1:T18 Arg2:T19	
T20	Measurement 459 475	Hematocrit (Hct)
T21	Value 476 481	> 50%
R9	Has_value Arg1:T20 Arg2:T21	
T22	Measurement 483 526	Estimated Glomerular Filtration Rate (eGFR)
T23	Value 527 538	< 30 ml/min
R10	Has_value Arg1:T22 Arg2:T23	
T24	Condition 551 571	deep vein thrombosis
T25	Condition 575 593	pulmonary embolism
T26	Condition 597 612	prostate cancer
T27	Condition 616 629	heart failure
T28	Qualifier 631 640	Class III
T29	Qualifier 631 636;645 647	Class IV
*	OR T29 T28
T30	Scope 631 647	Class III and IV
R11	Has_scope Arg1:T27 Arg2:T30	
*	OR T26 T27 T25 T24
